|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Ayala Pharmaceuticals, Inc. (AYLA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ayala Pharmaceuticals is a clinical stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Co.'s portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors. Gamma secretase is the enzyme responsible for Notch activation and, when inhibited, turns off the Notch pathway activation. Aberrant activation of the Notch pathway has long been implicated in various solid tumor and hematological cancers and has often been associated with more aggressive cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schindel Yair Chaim |
shareholder of 10% holder |
– – – |
2023-01-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,991,473) |
0 |
|
- |
|
| Sidransky David |
Director |
– • – |
2023-01-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(250) |
0 |
|
- |
|
| Yossi Maimon |
CFO, Secretary and Treasurer |
• • – |
2023-01-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(69,872) |
0 |
|
- |
|
| Gordon Gary B. |
Chief Medical Officer |
• – – |
2023-01-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,520) |
0 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2023-01-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(265,345) |
0 |
|
- |
|
| Yossi Maimon |
CFO, Secretary & Treasurer |
• – – |
2022-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
69,872 |
|
- |
|
| Gordon Gary B. |
Chief Medical Officer |
• – – |
2022-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
58,520 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2022-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
265,345 |
|
- |
|
| Gordon Gary B. |
Chief Medical Officer |
• – – |
2021-02-24 |
4 |
AS |
$17.46 |
$52,385 |
D/D |
(3,000) |
8,520 |
|
- |
|
| Gordon Gary B. |
Chief Medical Officer |
• – – |
2021-02-24 |
4 |
OE |
$5.16 |
$15,480 |
D/D |
3,000 |
11,520 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2021-02-24 |
4 |
AS |
$17.40 |
$187,919 |
D/D |
(10,800) |
145,345 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2021-02-23 |
4 |
AS |
$17.89 |
$127,483 |
D/D |
(7,126) |
156,145 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2021-02-22 |
4 |
AS |
$19.86 |
$301,813 |
D/D |
(15,200) |
163,271 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2021-01-21 |
4 |
AS |
$15.04 |
$21,147 |
D/D |
(1,406) |
178,471 |
|
- |
|
| Gordon Gary B. |
Chief Medical Officer |
• – – |
2021-01-20 |
4 |
AS |
$15.03 |
$45,084 |
D/D |
(3,000) |
8,520 |
|
- |
|
| Gordon Gary B. |
Chief Medical Officer |
• – – |
2021-01-20 |
4 |
OE |
$5.16 |
$15,480 |
D/D |
3,000 |
11,520 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2021-01-20 |
4 |
AS |
$15.03 |
$292,533 |
D/D |
(19,466) |
179,877 |
|
- |
|
| Mamluk Roni |
President & CEO |
• • – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
34,080 |
199,343 |
|
- |
|
| Yossi Maimon |
CFO, Secretary & Treasurer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
8,520 |
19,872 |
|
- |
|
| Gordon Gary B. |
Chief Medical Officer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
8,520 |
8,520 |
|
- |
|
| Sidransky David |
Director |
– • – |
2020-12-23 |
4 |
B |
$11.56 |
$46 |
I/I |
4 |
250 |
2.02 |
- |
|
| Sidransky David |
Director |
– • – |
2020-09-14 |
4 |
B |
$10.70 |
$11 |
I/I |
1 |
246 |
2.02 |
- |
|
| Sidransky David |
Director |
– • – |
2020-09-11 |
4 |
B |
$10.07 |
$101 |
I/I |
10 |
245 |
2.02 |
- |
|
| Sidransky David |
Director |
– • – |
2020-08-14 |
4 |
B |
$11.07 |
$55 |
I/I |
5 |
235 |
2.02 |
- |
|
| Sidransky David |
Director |
– • – |
2020-07-17 |
4 |
B |
$11.86 |
$47 |
I/I |
4 |
230 |
2.02 |
- |
|
40 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
